GlassScriptPhysician profile
Lezlie Mathews
NPI 1760570550
$9,548.17
in general payments reported to CMS, 2019-2025
32 companies · $2,138 in 2025
The $2,138 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,483 · 2022: $1,921 · 2023: $2,439 · 2024: $1,568 · 2025: $2,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,774 · Travel and Lodging: $1,371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,773.69 |
| Travel and Lodging | $1,370.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,325.95 | 2021-2025 | Cardiomems, Merlin@Home, Aveir |
| Novartis Pharmaceuticals Corporation | $1,347.34 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $530.25 | 2021-2025 | Camzyos, Eliquis |
| Pfizer INC. | $463.73 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $459.50 | 2021-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $446.17 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $418.71 | 2021-2024 | Verquvo |
| Abiomed | $342.60 | 2021-2025 | |
| Amgen INC. | $276.45 | 2021-2025 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $213.68 | 2021-2025 | |
| Lexicon Pharmaceuticals, INC. | $201.72 | 2024 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $196.33 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Recor Medical INC | $188.61 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Boston Scientific Corporation | $133.76 | 2022-2023 | Watchman Access System |
| Esperion Therapeutics, INC. | $113.41 | 2021-2025 | Nexletol |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $104.95 | 2025 | Ambulatory Monitoring & Diagnostics Undivided, Mcot |
| Biotronik INC. | $93.57 | 2022-2025 | Acticor 7 Vr-T Dx |
| Astellas Pharma US INC | $81.03 | 2021 | |
| Chiesi USA, INC. | $73.50 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $71.49 | 2023-2025 | Lifevest |
| Impulse Dynamics (USA) INC. | $65.00 | 2022-2023 | Optimizer |
| Heartflow, INC. | $64.72 | 2023-2024 | Ffrct |
| Amarin Pharma, INC. | $60.79 | 2021 | |
| Medtronic, INC. | $60.17 | 2021-2025 | Micra |
| Novo Nordisk INC | $53.71 | 2024 | Wegovy |
| Terumo Medical Corporation | $30.72 | 2022-2023 | Glidewire, Optitorque |
| United Therapeutics Corporation | $25.58 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $23.53 | 2021-2022 | |
| Bard Peripheral Vascular, INC. | $23.06 | 2025 | Rotarexs 6 F X 135 Cm |
| Silk Road Medical, INC. | $20.58 | 2021 | |
| Cvrx, INC. | $20.28 | 2025 | Barostim Neo System |
| Scpharmaceuticals INC. | $17.28 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lezlie Mathews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.